Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8161 to 8175 of 9030 results

  1. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued Reference number: GID-TA11120

    Technology appraisal guidance
    Discontinued

  2. Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]

    In development Reference number: GID-TA11762 Expected publication date:  28 July 2025

    Technology appraisal guidance
    In development

  3. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    Discontinued Reference number: GID-TA11442

    Technology appraisal guidance
    Discontinued

  4. Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]

    In development Reference number: GID-TA11441 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]

    In development Reference number: GID-TA11157 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

    Technology appraisal guidance
    Discontinued

  7. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

    Interventional procedures guidance
    Discontinued

  8. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued Reference number: GID-TA11244

    Technology appraisal guidance
    Discontinued

  9. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

    Quality standard
    In development

  10. Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]

    In development Reference number: GID-TA11792 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Deucravacitinib for treating active psoriatic arthritis [ID6561]

    In development Reference number: GID-TA11510 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

    In development Reference number: GID-TA11767 Expected publication date:  04 November 2026

    Technology appraisal guidance
    In development

  13. L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

    April 2026: This Medtech innovation briefing has been withdrawn because the L-Dex U400 device is no longer available in the UK.

    Withdrawn advice

  14. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

    In development Reference number: GID-TA10960 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

    Technology appraisal guidance
    In development